A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhibiting Radiographic Progression in Participants With Active Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhibiting Radiographic Progression in Participants With Active Psoriatic Arthritis
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Inclusion Criteria:
Exclusion Criteria:
St. John's, Newfoundland and Labrador A1C 5B8, Canada
Elblag, 82 300, Poland
Vladimir, 600023, Russia
Izo, 6310, Slovenia
Cheonan-si, 31151, South Korea
Seoul, 07061, South Korea
Santiago de Compostela, 15076, Spain
Cherkasy, 18009, Ukraine
Kharkiv, 61039, Ukraine
Kharkiv, 61058, Ukraine
Khmelnitsky, Ukraine
Kryvyi Rih, Ukraine
Kyiv, 03037, Ukraine
Kyiv, 03151, Ukraine
Poltava, Ukraine
Ternopil, Ukraine